State Street’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-27,093
| Closed | -$201K | – | 4233 |
|
|
2026
Q1 | $201K | Hold |
27,093
| – | – | ﹤0.01% | 3881 |
|
|
2025
Q4 | $170K | Buy |
27,093
+6,000
| +28% | +$35K | ﹤0.01% | 3932 |
|
|
2025
Q3 | $82.3K | Hold |
21,093
| – | – | ﹤0.01% | 4083 |
|
|
2025
Q2 | $96.6K | Hold |
21,093
| – | – | ﹤0.01% | 3982 |
|
|
2025
Q1 | $103K | Hold |
21,093
| – | – | ﹤0.01% | 3972 |
|
|
2024
Q4 | $142K | Buy |
21,093
+2,499
| +13% | +$18.6K | ﹤0.01% | 3919 |
|
|
2024
Q3 | $144K | Hold |
18,594
| – | – | ﹤0.01% | 3898 |
|
|
2024
Q2 | $112K | Sell |
18,594
-93,783
| -83% | -$713K | ﹤0.01% | 3975 |
|
|
2024
Q1 | $1.01M | Buy |
112,377
+772
| +0.7% | +$7.03K | ﹤0.01% | 3467 |
|
|
2023
Q4 | $1.06M | Buy |
111,605
+349
| +0.3% | +$3.07K | ﹤0.01% | 3473 |
|
|
2023
Q3 | $1.32M | Buy |
111,256
+1,684
| +2% | +$29.8K | ﹤0.01% | 3453 |
|
|
2023
Q2 | $2.68M | Sell |
109,572
-214,371
| -66% | -$5.58M | ﹤0.01% | 3276 |
|
|
2023
Q1 | $10.1M | Sell |
323,943
-101,453
| -24% | -$5.87M | ﹤0.01% | 2653 |
|
|
2022
Q4 | $29.9M | Buy |
425,396
+71,626
| +20% | +$5.31M | ﹤0.01% | 1964 |
|
|
2022
Q3 | $30.5M | Buy |
353,770
+280,261
| +381% | +$27.2M | ﹤0.01% | 1937 |
|
|
2022
Q2 | $6.08M | Sell |
73,509
-150,746
| -67% | -$13.3M | ﹤0.01% | 2994 |
|
|
2022
Q1 | $37.3M | Buy |
224,255
+90,258
| +67% | +$13M | ﹤0.01% | 1938 |
|
|
2021
Q4 | $22.4M | Buy |
133,997
+73,457
| +121% | +$8.29M | ﹤0.01% | 2401 |
|
|
2021
Q3 | $5.23M | Buy |
60,540
+9,061
| +18% | +$600K | ﹤0.01% | 3215 |
|
|
2021
Q2 | $2.79M | Buy |
51,479
+4,365
| +9% | +$248K | ﹤0.01% | 3487 |
|
|
2021
Q1 | $2.81M | Sell |
47,114
-3,297
| -7% | -$193K | ﹤0.01% | 3297 |
|
|
2020
Q4 | $2.63M | Sell |
50,411
-264
| -0.5% | -$14.7K | ﹤0.01% | 3254 |
|
|
2020
Q3 | $2.45M | Sell |
50,675
-658
| -1% | -$31.5K | ﹤0.01% | 3113 |
|
|
2020
Q2 | $2.66M | Buy |
51,333
+8,543
| +20% | +$431K | ﹤0.01% | 3064 |
|
|
2020
Q1 | $1.87M | Buy |
42,790
+19,972
| +88% | +$812K | ﹤0.01% | 3092 |
|
|
2019
Q4 | $915K | Sell |
22,818
-453
| -2% | -$13.9K | ﹤0.01% | 3427 |
|
|
2019
Q3 | $763K | Buy |
23,271
+1,632
| +8% | +$78.8K | ﹤0.01% | 3451 |
|
|
2019
Q2 | $1.67M | Buy |
21,639
+5,037
| +30% | +$783K | ﹤0.01% | 3306 |
|
|
2019
Q1 | $2.94M | Buy |
16,602
+9,314
| +128% | +$1.84M | ﹤0.01% | 3000 |
|
|
2018
Q4 | $1.72M | Buy |
7,288
+3,328
| +84% | +$813K | ﹤0.01% | 3172 |
|
|
2018
Q3 | $849K | Buy |
+3,960
| New | +$691K | ﹤0.01% | 3426 |
|
State Street's KZR Position: Q2 2026 in Review
State Street sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 27,093 shares — an estimated $201K sold.
State Street first reported a position in KZR in Q3 2018 and held it in 31 quarters. The position peaked at $37.3M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- State Street reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- State Street sold 27,093 Kezar Life Sciences shares in Q2 2026, an estimated $201K.
- State Street first reported a position in Kezar Life Sciences in Q3 2018 and held it in 31 quarters.
- State Street's Kezar Life Sciences position peaked at $37.3M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.